Cinacalcet Hydrochloride

Tier C — Watch / trade

Amgen

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：CaSR

Brand：Mimpara, Sensipar/Mimpara, Parareg, Regpara, Sensipar

Indications (approved)：Hypercalcaemia, Secondary hyperparathyroidism, Hyperparathyroidism

Regional status

Withdrawn

China

Approved

2014-06-27

Japan

Approved

2007-10-19

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Cinacalcet Hydrochloride?

Approved indications include: Hypercalcaemia, Secondary hyperparathyroidism, Hyperparathyroidism.

When does the Cinacalcet Hydrochloride patent expire?

No public expiry year is available for Cinacalcet Hydrochloride yet; this page updates once verified.

How do I get a quote for Cinacalcet Hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27